Clinical Trial Update: Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update evaluating dabrafenib, trametinib, and hydroxychloroquine in advanced pretreatment BRAF V600 mutant melanoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Hydroxychloroquine (hydroxychloroquine)
• Trametinib (trametinib)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Melanoma | Phase 1, Phase 2 | Status: UNKNOWN